

Carsten Denkert

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3472352/carsten-denkert-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

199
papers

15,385
citations

53
h-index

123
g-index

214
ext. papers

20,255
ext. citations

7.6
avg, IF

6.27
L-index

#	Paper	IF	Citations
199	Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1796-804 ²	2.2	1560
198	Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 105-13	2.2	1101
197	Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. <i>PLoS ONE</i> , 2012 , 7, e51862	3.7	749
196	Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. <i>Lancet Oncology, The</i> , 2018 , 19, 40-50	21.7	730
195	Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. <i>Journal of Clinical Oncology</i> , 2015 , 33, 983-91	2.2	650
194	Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 747-56	21.7	603
193	Pembrolizumab for Early Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2020 , 382, 810-821	59.2	599
192	Clinical relevance of host immunity in breast cancer: from TILs to the clinic. <i>Nature Reviews Clinical Oncology</i> , 2016 , 13, 228-41	19.4	429
191	Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. <i>New England Journal of Medicine</i> , 2012 , 366, 299-309	59.2	411
190	Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. <i>Lancet, The</i> , 2017 , 389, 2430-2442	40	394
189	Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. <i>JAMA Oncology</i> , 2015 , 1, 448-54	13.4	359
188	Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. <i>Cancer Research</i> , 2006 , 66, 10795-804	10.1	323
187	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma	5.1	299
186	Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in</i>	5.1	293
185	Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. <i>Journal of Clinical Oncology</i> , 2019 , 37, 559-569	2.2	282
184	Metabolite profiling of human colon carcinoma--deregulation of TCA cycle and amino acid turnover. <i>Molecular Cancer</i> , 2008 , 7, 72	42.1	235
183	Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 345-356	21.7	234

182	Response-guided neoadjuvant chemotherapy for breast cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3623-30	2.2	231
181	Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial. <i>JAMA Oncology</i> , 2017 , 3, 1378-1385	13.4	210
180	Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. <i>Seminars in Cancer Biology</i> , 2018 , 52, 16-25	12.7	181
179	Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. <i>Cancer</i> , 2003 , 97, 2978-87	6.4	176
178	Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. <i>American Journal of Pathology</i> , 2002 , 160, 893-903	5.8	175
177	Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. <i>Oncotarget</i> , 2016 , 7, 1486-99	3.3	168
176	Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, 545-553	13.4	162
175	Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. <i>Modern Pathology</i> , 2016 , 29, 1155-64	9.8	154
174	The landscape of metastatic progression patterns across major human cancers. <i>Oncotarget</i> , 2015 , 6, 570-83	3.3	152
173	Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. <i>Modern Pathology</i> , 2015 , 28, 1185-201	9.8	144
172	Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression. <i>Cancer Research</i> , 2004 , 64, 189-95	10.1	143
171	Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2. <i>Modern Pathology</i> , 2006 , 19, 1261-9	9.8	138
170	Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	131
169	Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma. <i>Clinical Cancer Research</i> , 2004 , 10, 5580-6	12.9	129
168	Breast cancer. <i>Lancet, The</i> , 2021 , 397, 1750-1769	40	126
167	Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 5747-5754	12.9	116
166	Ki67 measured after neoadjuvant chemotherapy for primary breast cancer. <i>Clinical Cancer Research</i> , 2013 , 19, 4521-31	12.9	110
165	Strategies for developing Ki67 as a useful biomarker in breast cancer. <i>Breast</i> , 2015 , 24 Suppl 2, S67-72	3.6	102

164	Expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in primary human ovarian carcinoma. <i>International Journal of Cancer</i> , 2002 , 102, 507-13	7.5	99
163	Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 808-819	9.7	95
162	Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference. <i>Oncogene</i> , 2003 , 22, 8653-61	9.2	85
161	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. <i>Journal of Pathology</i> , 2020 , 250, 667-684	9.4	83
160	Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. <i>BMC Medicine</i> , 2018 , 16, 179	11.4	83
159	A prognostic gene expression index in ovarian cancer - validation across different independent data sets. <i>Journal of Pathology</i> , 2009 , 218, 273-80	9.4	80
158	KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. <i>Journal of Molecular Diagnostics</i> , 2010 , 12, 35-42	5.1	77
157	Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012 , 460, 251-9	5.1	75
156	Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery. <i>Genome Medicine</i> , 2012 , 4, 37	14.4	74
155	Standardized Ki67 Diagnostics Using Automated Scoring--Clinical Validation in the GeparTrio Breast Cancer Study. <i>Clinical Cancer Research</i> , 2015 , 21, 3651-7	12.9	73
154	Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue--a new option for predictive biomarker assessment in breast cancer. <i>Diagnostic Molecular Pathology</i> , 2011 , 20, 1-10		71
153	Tumor infiltrating lymphocytes in early breast cancer. <i>Breast</i> , 2018 , 37, 207-214	3.6	64
152	Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients. <i>Oncotarget</i> , 2014 , 5, 8147-60	3.3	64
151	Prognostic impact of cyclooxygenase-2 in breast cancer. <i>Clinical Breast Cancer</i> , 2004 , 4, 428-33	3	63
150	Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival. <i>Genes Chromosomes and Cancer</i> , 2016 , 55, 626-39	5	63
149	Classical pathology and mutational load of breast cancer - integration of two worlds. <i>Journal of Pathology: Clinical Research</i> , 2015 , 1, 225-38	5.3	57
148	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020 , 6, 17	7.8	54
147	Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). <i>European Journal of Cancer</i> , 2017 , 85, 133-145	7.5	54

146	The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions. <i>PLoS ONE</i> , 2013 , 8, e68252	3.7	52
145	Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences. <i>Oncotarget</i> , 2014 , 5, 9952-65	3.3	52
144	An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer. <i>Modern Pathology</i> , 2019 , 32, 59-69	9.8	51
143	Accumulated Metabolites of Hydroxybutyric Acid Serve as Diagnostic and Prognostic Biomarkers of Ovarian High-Grade Serous Carcinomas. <i>Cancer Research</i> , 2016 , 76, 796-804	10.1	50
142	Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma. <i>European Journal of Cancer</i> , 2017 , 83, 290-301	7.5	49
141	Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial. <i>European Journal of Cancer</i> , 2019 , 101, 181-192	7.5	49
140	Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2020 , 6, 16	7.8	47
139	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. <i>Annals of Oncology</i> , 2021 , 32, 1216-1235	10.3	44
138	Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer. <i>BMC Clinical Pathology</i> , 2015 , 15, 20	3	43
137	pT but not pN stage of the 8th TNM classification significantly improves prognostication in pancreatic ductal adenocarcinoma. <i>European Journal of Cancer</i> , 2017 , 84, 121-129	7.5	42
136	PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma. <i>Oncotarget</i> , 2017 , 8, e127977	7.2	40
135	An inhibitor of stress-activated MAP-kinases reduces invasion and MMP-2 expression of malignant melanoma cells. <i>Clinical and Experimental Metastasis</i> , 2002 , 19, 79-85	4.7	40
134	Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden. <i>Oncotarget</i> , 2018 , 9, e1526613	7.2	40
133	Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy. <i>Oncotarget</i> , 2016 , 7, 67686-67698	3.3	36
132	Neoadjuvant treatment of breast cancer--Clinical and research perspective. <i>Breast</i> , 2015 , 24 Suppl 2, S73-7	3.6	35
131	Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer. <i>BMC Medicine</i> , 2015 , 13, 177	11.4	35
130	Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 2675-83	12.9	35
129	Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 104-104	2.2	35

128	Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1518-1530	2.2	35
127	High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism. <i>Oncotarget</i> , 2017 , 8, 102912-102922	3.3	34
126	Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. <i>Lancet Oncology</i> , 2021 , 22, 1151-1161	21.7	32
125	Dual Blockade with Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70). <i>Clinical Cancer Research</i> , 2015 , 21, 2924-31	12.9	31
124	Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan-cancer survey with implications for the use of immune checkpoint inhibitors. <i>Genes Chromosomes and Cancer</i> , 2017 , 56, 651-659	5	30
123	Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types. <i>BMC Medical Genomics</i> , 2017 , 10, 74	3.7	30
122	GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (HRD).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 506-506	2.2	30
121	Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance. <i>Clinical Cancer Research</i> , 2016 , 22, 5238-5248	12.9	30
120	Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017 , 1868, 527-537	11.2	29
119	Does long-term survival in patients with pancreatic cancer really exist? Results from the CONKO-001 study. <i>Journal of Surgical Oncology</i> , 2013 , 108, 398-402	2.8	29
118	Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.. <i>New England Journal of Medicine</i> , 2022 , 386, 556-567	59.2	29
117	Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytes. <i>Breast</i> , 2019 , 44, 29-32	3.6	29
116	Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy. <i>European Journal of Cancer</i> , 2016 , 53, 65-74	7.5	27
115	Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study. <i>European Journal of Cancer</i> , 2019 , 114, 76-88	7.5	25
114	Wilms tumor protein 1 (WT1)-- not only a diagnostic but also a prognostic marker in high-grade serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2016 , 140, 494-502	4.9	24
113	Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. <i>Breast Cancer Research and Treatment</i> , 2018 , 167, 59-71	4.4	23
112	Tissue-Based Metabolomics to Analyze the Breast Cancer Metabolome. <i>Recent Results in Cancer Research</i> , 2016 , 207, 157-75	1.5	23
111	KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS602-TPS602	2.2	23

110	Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma. <i>British Journal of Cancer</i> , 2018 , 118, 1485-1491	8.7	23
109	Overexpression of cyclooxygenase-2 in human prostate carcinoma and prostatic intraepithelial neoplasia-association with increased expression of Polo-like kinase-1. <i>Prostate</i> , 2007 , 67, 361-9	4.2	22
108	Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial. <i>Clinical Cancer Research</i> , 2019 , 25, 3986-3995	12.9	21
107	Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer: A Secondary Analysis of the GeparOcto Randomized Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 744-748	13.4	21
106	FGFR4 overexpression and hotspot mutations in metastatic ER+ breast cancer are enriched in the lobular subtype. <i>Npj Breast Cancer</i> , 2019 , 5, 19	7.8	21
105	Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neoadjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 501-501	2.2	21
104	Morphological and molecular breast cancer profiling through explainable machine learning. <i>Nature Machine Intelligence</i> , 2021 , 3, 355-366	22.5	20
103	Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy. <i>Seminars in Immunopathology</i> , 2011 , 33, 341-51	12	19
102	Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrightNESS Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2021 , 7, 603-608	13.4	19
101	DNA methylation profiling reliably distinguishes pulmonary enteric adenocarcinoma from metastatic colorectal cancer. <i>Modern Pathology</i> , 2019 , 32, 855-865	9.8	18
100	Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer. <i>Neoplasia</i> , 2018 , 20, 280-288	6.4	17
99	Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials. <i>Annals of Surgical Oncology</i> , 2019 , 26, 3892-3901	3.1	17
98	Tumor-infiltrating lymphocytes in breast cancer: A new predictor for responses to therapy. <i>Oncotarget</i> , 2014 , 3, e27926	7.2	17
97	Cytokine-suppressive anti-inflammatory drugs (CSAIDs) inhibit invasion and MMP-1 production of ovarian carcinoma cells. <i>Cancer Letters</i> , 2003 , 195, 101-9	9.9	17
96	Fulminant Intravascular Disseminating Malignant Melanoma Mimicking Acute Leukemia. <i>Blood</i> , 1999 , 94, 1483-1484	2.2	17
95	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2021 , 7, 150	7.8	17
94	loncopy: a novel method for calling copy number alterations in amplicon sequencing data including significance assessment. <i>Oncotarget</i> , 2016 , 7, 13236-47	3.3	17
93	PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy. <i>Cancer Research and Treatment</i> , 2020 , 52, 689-696	5.2	17

92	P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment. <i>Pathology Research and Practice</i> , 2016 , 212, 726-34	3.4	15
91	A Non-interventional Clinical Trial Assessing Immune Responses After Radiofrequency Ablation of Liver Metastases From Colorectal Cancer. <i>Frontiers in Immunology</i> , 2019 , 10, 2526	8.4	15
90	Outcome after neoadjuvant chemotherapy in elderly breast cancer patients - a pooled analysis of individual patient data from eight prospectively randomized controlled trials. <i>Oncotarget</i> , 2018 , 9, 15168-75	3.3	15
89	Clinical relevance and concordance of HER2 status in local and central testing-an analysis of 1581 HER2-positive breast carcinomas over 12 years. <i>Modern Pathology</i> , 2018 , 31, 607-615	9.8	14
88	Mutational profiles of Brenner tumors show distinctive features uncoupling urothelial carcinomas and ovarian carcinoma with transitional cell histology. <i>Genes Chromosomes and Cancer</i> , 2017 , 56, 758-766	5	14
87	Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrences. <i>Breast Cancer Research</i> , 2021 , 23, 1	8.3	14
86	Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment. <i>Cell Death and Differentiation</i> , 2021 , 28, 2778-2796	12.7	13
85	Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network. <i>Human Pathology</i> , 2019 , 85, 299-308	3.7	13
84	Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 Trial. <i>Clinical Cancer Research</i> , 2020 , 26, 3732-3739	12.9	13
83	Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox. <i>Lancet Oncology</i> , 2021 , 22, e18-e28	21.7	13
82	Linking CREB function with altered metabolism in murine fibroblast-based model cell lines. <i>Oncotarget</i> , 2017 , 8, 97439-97463	3.3	12
81	Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials. <i>European Journal of Cancer</i> , 2021 , 148, 159-170	7.5	12
80	Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy. <i>Breast Cancer Research</i> , 2019 , 21, 142	8.3	12
79	Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials. <i>European Journal of Cancer</i> , 2020 , 130, 92-101	7.5	11
78	Comprehensive analysis of clinico-pathological data reveals heterogeneous relations between atherosclerosis and cancer. <i>Journal of Clinical Pathology</i> , 2014 , 67, 482-90	3.9	11
77	Prediction of Response to Neoadjuvant Chemotherapy: New Biomarker Approaches and Concepts. <i>Breast Care</i> , 2011 , 6, 265-272	2.4	11
76	Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial. <i>Oncotarget</i> , 2015 , 6, 30306-16	3.3	11
75	Hypoxia-mediated alterations and their role in the HER-2/neuregulated CREB status and localization. <i>Oncotarget</i> , 2016 , 7, 52061-52084	3.3	10

74	Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 2584-2591	12.9	10
73	Matrix stiffness drives stromal autophagy and promotes formation of a protumorigenic niche. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	10
72	Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial. <i>International Journal of Cancer</i> , 2019 , 145, 857-868	7.5	9
71	Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor. <i>Clinical Cancer Research</i> , 2018 , 24, 3358-3365	12.9	9
70	Prioritization of metabolic genes as novel therapeutic targets in estrogen-receptor negative breast tumors using multi-omics data and text mining. <i>Oncotarget</i> , 2019 , 10, 3894-3909	3.3	9
69	A multicentre analytical comparison study of inter-reader and inter-assay agreement of four programmed death-ligand 1 immunohistochemistry assays for scoring in triple-negative breast cancer. <i>Histopathology</i> , 2021 , 78, 567-577	7.3	9
68	Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. <i>Npj Breast Cancer</i> , 2020 , 6, 15	7.8	8
67	A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial. <i>Clinical Cancer Research</i> , 2020 , 26, 1896-1904	12.9	7
66	Morphology and tumour-infiltrating lymphocytes in high-stage, high-grade serous ovarian carcinoma correlated with long-term survival. <i>Histopathology</i> , 2018 , 73, 1002-1012	7.3	7
65	Cytokeratin 5/6 expression, prognosis, and association with estrogen receptor β in high-grade serous ovarian carcinoma. <i>Human Pathology</i> , 2017 , 67, 30-36	3.7	6
64	Morphomolecular analysis of the immune tumor microenvironment in human head and neck cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 1443-1454	7.4	6
63	Hent1 expression in patients with pancreatic cancer treated with gemcitabine after curative intended resection: Results from the CONKO-001 trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4124-4124 ^{2.2}	2.2	6
62	Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer. <i>International Journal of Cancer</i> , 2020 , 147, 266-276	7.5	6
61	Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial. <i>Breast Cancer Research and Treatment</i> , 2019 , 176, 557-568	4.4	5
60	Hotspot ESR1 mutations are multimodal and contextual modulators of breast cancer metastasis.. <i>Cancer Research</i> , 2022 ,	10.1	5
59	APOBEC3B protein expression and mRNA analyses in patients with high-grade serous ovarian carcinoma. <i>Histology and Histopathology</i> , 2019 , 34, 405-417	1.4	5
58	Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC 2020 , 8,		5
57	Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial. <i>JAMA Oncology</i> , 2021 , 7, 1291-1301	13.4	5

56	Semiconductor sequencing: how many flows do you need?. <i>Bioinformatics</i> , 2015 , 31, 1199-203	7.2	4
55	Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer.. <i>Npj Breast Cancer</i> , 2022 , 8, 3	7.8	4
54	Correlation of PIK3CA mutation with pathological complete response in primary HER2-positive breast cancer: Combined analysis of 967 patients from three prospective clinical trials.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 511-511	2.2	4
53	Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrightNess phase III study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 510-510	2.2	4
52	KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS601-TPS601	2.2	4
51	loncopy: an R Shiny app to call copy number alterations in targeted NGS data. <i>BMC Bioinformatics</i> , 2018 , 19, 157	3.6	3
50	Expression of immunologic genes in triple-negative and HER2-positive breast cancer in the neoadjuvant GEPARSIXTO trial: Prediction of response to carboplatin-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 510-510	2.2	3
49	Investigating denosumab as add-on neoadjuvant treatment for hormone receptor-negative, RANK-positive or RANK-negative primary breast cancer and two different nab-Paclitaxel schedules - 2x2 factorial design (GeparX).. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS635-TPS635	2.2	3
48	NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in Patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS603-TPS603	2.2	3
47	MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial. <i>PLoS ONE</i> , 2020 , 15, e0238021	3.7	3
46	HER2-low-positive breast cancer from four neoadjuvant clinical trials - AuthorsReply. <i>Lancet Oncology</i> , 2021 , 22, e427	21.7	3
45	How VEGF-A and its splice variants affect breast cancer development - clinical implications.. <i>Cellular Oncology (Dordrecht)</i> , 2022 , 1	7.2	3
44	Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017 , 470, 143-151	5.1	2
43	Abstract GS3-01: Investigating denosumab as an add-on treatment to neoadjuvant chemotherapy and two different nab-paclitaxel schedules in a 2x2 design in primary breast cancer - First results of the GeparX study 2020 ,		2
42	A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel / carboplatin followed by epirubicin / cyclophosphamide as neoadjuvant chemotherapy in patients with HER2-negative early breast cancer and homologous recombination deficiency (HRD): GeparOLA.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS1096-TPS1096	2.2	2
41	Gene expression profiling using Nanostring technology to predict surgical outcome in advanced primary high grade serous ovarian cancer (HGSOC) patients (pts). Study of the Tumor Bank Ovarian Cancer (TOC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 5569-5569	2.2	2
40	Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness. <i>Npj Breast Cancer</i> , 2021 , 7, 142	7.8	2
39	PARP-1 expression as a prognostic factor in Desmoid-type fibromatosis. <i>Annals of Diagnostic Pathology</i> , 2020 , 44, 151442	2.2	2

38	Subgroup of post-neoadjuvant luminal-B tumors assessed by HTG in PENELOPE-B investigating palbociclib in high risk HER2-/HR+ breast cancer with residual disease.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 519-519	2.2	2
37	Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group. <i>Cancers</i> , 2021 , 13,	6.6	2
36	Tumour-Infiltrating Lymphocytes (TILs) in Breast Cancer: a Predictive or a Prognostic Marker?. <i>Current Breast Cancer Reports</i> , 2015 , 7, 59-70	0.8	1
35	Reply to L. Ozretić et al. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4588-4589	2.2	1
34	Lack of correlation of neoantigens arising from tumor somatic mutations with tumor infiltrating lymphocytes (TILs) or survival in HER2-positive breast cancer (HER2+ BC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 613-613	2.2	1
33	Serum carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11505-11505	2.2	1
32	Influence of cytotoxic tumor-infiltrating T lymphocytes on outcome in resectable pancreatic cancer: Results from the CONKO 001 trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 281-281	2.2	1
31	Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early	7.5	1
30	Signatures of mutational processes and response to neoadjuvant chemotherapy in breast cancer: A genome-based investigation in the neoadjuvant GeparSepto trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 574-574	2.2	1
29	SPARC in pancreatic cancer: Results from the CONKO-001 study.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4016-4016	2.2	1
28	Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: German Expert Opinions on the 17th International St. Gallen Consensus Conference. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021 , 81, 637-653	2	1
27	Validation of a Nomogram Predicting Non-Sentinel Lymph Node Metastases among Patients with Breast Cancer after Primary Systemic Therapy - a transSENTINA Substudy. <i>Breast Care</i> , 2018 , 13, 440-446 ^{2.4}	2.4	1
26	Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood.. <i>Cancer Immunology, Immunotherapy</i> , 2022 , 1	7.4	1
25	Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses. <i>Cancer Research</i> , 2022 , 82, GS1-01-GS1-01	10.1	1
24	Correlation of the tumor mutational burden with the composition of the immune cell subpopulations in peripheral blood of triple-negative breast cancer patients undergoing neoadjuvant therapy with durvalumab: Results from the prospectively randomized GeparNuevo trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 588-588	2.2	0
23	TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer. <i>BMC Cancer</i> , 2021 , 21, 920	4.8	0
22	Reply to Y. Kawamura et al. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3090-3091	2.2	0
21	Gene Expression Analyses in Early Breast Carcinoma [Quo Vadis?]. <i>Senologie - Zeitschrift Für Mammadiagnostik Und -therapie</i> , 2017 , 14, 209-213	0	

20	Immunological Mechanisms in Breast Cancer - from Bench to Bedside. <i>Breast Care</i> , 2016 , 11, 93-4	2.4
19	Comparison of risk assessment in 1652 early ER positive, HER2 negative breast cancer in a real-world data set: classical pathological parameters vs. 12-gene molecular assay (EndoPredict). <i>Breast Cancer Research and Treatment</i> , 2021 , 191, 327	4.4
18	DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status. <i>Clinical Epigenetics</i> , 2021 , 13, 184	7.7
17	Successful generation of patient derived xenografts and patient derived 3D cultures as preclinical models for breast cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 12080-12080	2.2
16	Comparison of an automated cartridge-based system for mRNA assessment with central immunohistochemistry in the neoadjuvant GeparX trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3075-3075 ^{2,2}	
15	Prognostic score for Luminal A-like breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 525-525 ₂	
14	Inhibition of MEK1 increases carboplatin sensitivity in ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5557-5557	2.2
13	A randomized phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto).. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS1101-TPS1101	2.2
12	Development and validation of a new prognostic score on 4,646 patients with luminal-like breast cancer (BC) enrolled in 7 randomized prospective trials.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 529-529	2.2
11	Risk assessment after neoadjuvant chemotherapy in luminal breast cancer: A prospectively planned validation of gene expression based and clinical prognostic scores in 428 residual tumor samples from two neoadjuvant clinical trials.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 522-522	2.2
10	Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal b/HER2 normal breast cancer (GENEVIEVE).. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS1138-TPS1138	2.2
9	Hormone receptor-dependent regulation of ABAT and beta-alanine metabolism in breast cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 11112-11112	2.2
8	PIK3CA mutations in primary HER2-positive and triple negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 11061-11061	2.2
7	Behandlung von Patientinnen mit frühem Mammakarzinom: Evidenz, Kontroversen, Konsens □ Meinungsbild deutscher Expert*innen zur 17. Internationalen St.-Gallen-Konsensuskonferenz. <i>Senologie - Zeitschrift Für Mammadiagnostik Und -therapie</i> , 2021 , 18, 163-181	0
6	Abstract P5-13-36: Germline BRCA1/2 and other predisposition genes in high-risk early-stage HR+/HER2- breast cancer (BC) patients treated with endocrine therapy (ET) with or without palbociclib: A secondary analysis from the PENELOPE-B study. <i>Cancer Research</i> , 2022 , 82, P5-13-36-P5-13-36	10.1
5	Abstract PD2-04: Molecular plasticity of luminal breast cancer and response to CDK 4/6 inhibition - The biomarker program of the PENELOPE-B trial investigating post-neoadjuvant palbociclib. <i>Cancer Research</i> , 2022 , 82, PD2-04-PD2-04	10.1
4	Abstract P4-04-14: Immunological markers in patients with breast cancer occurring during pregnancy - Results from GBG BCP study. <i>Cancer Research</i> , 2022 , 82, P4-04-14-P4-04-14	10.1
3	Abstract PD9-07: Mdm2 gene amplification in estrogen receptor-positive breast cancer cells is associated with enhanced solid tumor growth and pronounced metastatic potential in humanized tumor mice (HTM) and a poor outcome of patients with luminal breast cancer. <i>Cancer Research</i> , 2022 , 82, PD9-07-PD9-07	10.1

- 2 Abstract P2-12-03: Phenotype shifting in early breast cancer with and without primary systemic treatment: A retrospective cohort analysis correlating core needle biopsies and excisional biopsies in 1250 consecutive real-world cases. *Cancer Research*, **2022**, 82, P2-12-03-P2-12-03 10.1
- 1 Polycomb Protein BMI-1 as a Potential Therapeutic Target in Mucinous Ovarian Cancer.. *Anticancer Research*, **2022**, 42, 1739-1747 2.3